About Peroxisomal biogenesis factor 3
Peroxisomal biogenesis factor 3 (PEX3) is a protein
from Homo sapiens identified by UniProt accession
P56589, 373 residues long.
MolForge cross-references it against 0 known binders and
52 disease associations.
Target properties
| Protein name | Peroxisomal biogenesis factor 3 |
| UniProt accession | P56589 |
| Gene | PEX3 |
| Organism | Homo sapiens |
| Length | 373 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (52)
Diseases linked to this target (Open Targets).
- peroxisome biogenesis disorder 10A (Zellweger) · score 0.76
- Zellweger syndrome · score 0.73
- peroxisome biogenesis disorder · score 0.57
- neurodegenerative disease · score 0.50
- peroxisome biogenesis disorder 1A (Zellweger) · score 0.44
- Peroxisome biogenesis disorder-Zellweger syndrome spectrum · score 0.44
- peroxisome biogenesis disorder, complementation group 7 · score 0.37
- genetic disorder · score 0.18
- cutaneous melanoma · score 0.13
- PHF-tau measurement · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P56589-F1 | alphafold | PREDICTED | 88.88 | — |
Amino-acid sequence (373 residues)
MLRSVWNFLK RHKKKCIFLG TVLGGVYILG KYGQKKIREI QEREAAEYIA QARRQYHFES NQRTCNMTVL SMLPTLREAL MQQLNSESLT ALLKNRPSNK LEIWEDLKII SFTRSTVAVY STCMLVVLLR VQLNIIGGYI YLDNAAVGKN GTTILAPPDV QQQYLSSIQH LLGDGLTELI TVIKQAVQKV LGSVSLKHSL SLLDLEQKLK EIRNLVEQHK SSSWINKDGS KPLLCHYMMP DEETPLAVQA CGLSPRDITT IKLLNETRDM LESPDFSTVL NTCLNRGFSR LLDNMAEFFR PTEQDLQHGN SMNSLSSVSL PLAKIIPIVN GQIHSVCSET PSHFVQDLLT MEQVKDFAAN VYEAFSTPQQ LEK
Explore Peroxisomal biogenesis factor 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets